Texas Renal Ventures in Fort Worth, Texas - Dialysis Center

Texas Renal Ventures is a medicare approved dialysis facility center in Fort Worth, Texas and it has 29 dialysis stations. It is located in Tarrant county at 251 University Dr, Fort Worth, TX, 76107. You can reach out to the office of Texas Renal Ventures at (817) 870-5002. This dialysis clinic is managed and/or owned by Renal Ventures Management. Texas Renal Ventures has the following ownership type - Profit. It was first certified by medicare in September, 2000. The medicare id for this facility is 452819 and it accepts patients under medicare ESRD program.

Dialysis Center Profile

NameTexas Renal Ventures
Location251 University Dr, Fort Worth, Texas
No. of Dialysis Stations 29
Medicare ID452819
Managed ByRenal Ventures Management
Ownership TypeProfit
Late Shifts No

Contact Information


251 University Dr, Fort Worth, Texas, 76107
(817) 870-5002

News Archive

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven's Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

BrainsWay receives FDA clearance for Deep TMS system to treat adults with obsessive-compulsive disorder

BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

New study shows how anterior cingulate cortex can be stimulated to control pain

A new study by a University of Texas at Arlington physics team in collaboration with bioengineering and psychology researchers shows for the first time how a small area of the brain can be optically stimulated to control pain.

Researchers profile over 6000 genes in the two primary types of normal breast cells

For several years, scientists have attempted to identify gene expression changes, using microarrays or ‘DNA chips', in order to understand and predict breast cancer onset, progression, and clinical outcome.

Read more Medical News

› Verified 4 days ago


Map and Direction



NPI Associated with this Dialysis Facility:

Dialysis Facilities may have multiple NPI numbers. We have found possible NPI number/s associated with Texas Renal Ventures from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number1568487585
Doing Business AsTexas Renal Ventures, Lp, Lllp
Address251 University Dr Fort Worth, Texas, 76107
Phone Number(817) 870-5002

News Archive

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven's Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

BrainsWay receives FDA clearance for Deep TMS system to treat adults with obsessive-compulsive disorder

BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

New study shows how anterior cingulate cortex can be stimulated to control pain

A new study by a University of Texas at Arlington physics team in collaboration with bioengineering and psychology researchers shows for the first time how a small area of the brain can be optically stimulated to control pain.

Researchers profile over 6000 genes in the two primary types of normal breast cells

For several years, scientists have attempted to identify gene expression changes, using microarrays or ‘DNA chips', in order to understand and predict breast cancer onset, progression, and clinical outcome.

Read more Medical News

› Verified 4 days ago


Survey of Patient's Experiences

Nephrologists Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that nephrologists always communicated and cared for them.60%67%
Patients who reported that nephrologists usually communicated and cared for them.20%15%
Patients who reported that nephrologists sometimes or never communicated and cared for them.20%18%
Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).52%60%
Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).33%26%
Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).15%14%

News Archive

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven's Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

BrainsWay receives FDA clearance for Deep TMS system to treat adults with obsessive-compulsive disorder

BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

New study shows how anterior cingulate cortex can be stimulated to control pain

A new study by a University of Texas at Arlington physics team in collaboration with bioengineering and psychology researchers shows for the first time how a small area of the brain can be optically stimulated to control pain.

Researchers profile over 6000 genes in the two primary types of normal breast cells

For several years, scientists have attempted to identify gene expression changes, using microarrays or ‘DNA chips', in order to understand and predict breast cancer onset, progression, and clinical outcome.

Read more Medical News

› Verified 4 days ago

Dialysis Center Staff Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible.52%62%
Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible.25%20%
Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free.23%18%
Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).57%62%
Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).30%26%
Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).13%12%

News Archive

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven's Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

BrainsWay receives FDA clearance for Deep TMS system to treat adults with obsessive-compulsive disorder

BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

New study shows how anterior cingulate cortex can be stimulated to control pain

A new study by a University of Texas at Arlington physics team in collaboration with bioengineering and psychology researchers shows for the first time how a small area of the brain can be optically stimulated to control pain.

Researchers profile over 6000 genes in the two primary types of normal breast cells

For several years, scientists have attempted to identify gene expression changes, using microarrays or ‘DNA chips', in order to understand and predict breast cancer onset, progression, and clinical outcome.

Read more Medical News

› Verified 4 days ago

Overall Dialysis Center Performance Ratings

Experience MeasureProviderNational Avg.
Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. 83%80%
Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them.17%20%
Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible).66%68%
Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible).24%20%
Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible).10%12%

News Archive

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven's Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

BrainsWay receives FDA clearance for Deep TMS system to treat adults with obsessive-compulsive disorder

BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

New study shows how anterior cingulate cortex can be stimulated to control pain

A new study by a University of Texas at Arlington physics team in collaboration with bioengineering and psychology researchers shows for the first time how a small area of the brain can be optically stimulated to control pain.

Researchers profile over 6000 genes in the two primary types of normal breast cells

For several years, scientists have attempted to identify gene expression changes, using microarrays or ‘DNA chips', in order to understand and predict breast cancer onset, progression, and clinical outcome.

Read more Medical News

› Verified 4 days ago

Patient Distribution

Anemia Management

Dialysis patients with Hemoglobin data60
Medicare patients who had average hemoglobin (hgb) less than 10 g/dL42

News Archive

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven's Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

BrainsWay receives FDA clearance for Deep TMS system to treat adults with obsessive-compulsive disorder

BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

New study shows how anterior cingulate cortex can be stimulated to control pain

A new study by a University of Texas at Arlington physics team in collaboration with bioengineering and psychology researchers shows for the first time how a small area of the brain can be optically stimulated to control pain.

Researchers profile over 6000 genes in the two primary types of normal breast cells

For several years, scientists have attempted to identify gene expression changes, using microarrays or ‘DNA chips', in order to understand and predict breast cancer onset, progression, and clinical outcome.

Read more Medical News

› Verified 4 days ago

Dialysis Adequacy

Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.

  • Hemodialysis
    Adult patients getting regular hemodialysis at the center83
    Adult patient months included in Kt/V greater than or equal to 1.2753
    Percentage of adult patients getting regular hemodialysis at the center97
    Percentage of pediatric patients getting regular hemodialysis at the center

    News Archive

    Quethera receives seed investment funding to develop gene therapy for glaucoma

    Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven's Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

    BrainsWay receives FDA clearance for Deep TMS system to treat adults with obsessive-compulsive disorder

    BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

    New study shows how anterior cingulate cortex can be stimulated to control pain

    A new study by a University of Texas at Arlington physics team in collaboration with bioengineering and psychology researchers shows for the first time how a small area of the brain can be optically stimulated to control pain.

    Researchers profile over 6000 genes in the two primary types of normal breast cells

    For several years, scientists have attempted to identify gene expression changes, using microarrays or ‘DNA chips', in order to understand and predict breast cancer onset, progression, and clinical outcome.

    Read more Medical News

    › Verified 4 days ago

  • Peritoneal Dialysis
    Adult patients getting regular peritoneal dialysis at the center21
    Adult patient months included in Kt/V greater than or equal to 1.7162
    Percentage of adult patients getting regular peritoneal dialysis at the center90
    Percentage of pediatric patients getting regular peritoneal dialysis at the center

    News Archive

    Quethera receives seed investment funding to develop gene therapy for glaucoma

    Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven's Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

    BrainsWay receives FDA clearance for Deep TMS system to treat adults with obsessive-compulsive disorder

    BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

    New study shows how anterior cingulate cortex can be stimulated to control pain

    A new study by a University of Texas at Arlington physics team in collaboration with bioengineering and psychology researchers shows for the first time how a small area of the brain can be optically stimulated to control pain.

    Researchers profile over 6000 genes in the two primary types of normal breast cells

    For several years, scientists have attempted to identify gene expression changes, using microarrays or ‘DNA chips', in order to understand and predict breast cancer onset, progression, and clinical outcome.

    Read more Medical News

    › Verified 4 days ago

Mineral and Bone Disorder

An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Texas Renal Ventures with elevated calcium levels.

Patients with hypercalcemia103
Hypercalcemia patient months935
Hypercalcemia patients with serumcalcium greater than 10.2 mg1
Patients with Serumphosphor105
Patients with Serumphosphor less than 3.5 mg/dL7
Patients with Serumphosphor from 3.5 to 4.5 mg/dL21
Patients with Serumphosphor from 4.6 to 5.5 mg/dL27
Patients with Serumphosphor from 5.6 to 7 mg/dL28
Patients with Serumphosphor greater than 7 mg/dL17

News Archive

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven's Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

BrainsWay receives FDA clearance for Deep TMS system to treat adults with obsessive-compulsive disorder

BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

New study shows how anterior cingulate cortex can be stimulated to control pain

A new study by a University of Texas at Arlington physics team in collaboration with bioengineering and psychology researchers shows for the first time how a small area of the brain can be optically stimulated to control pain.

Researchers profile over 6000 genes in the two primary types of normal breast cells

For several years, scientists have attempted to identify gene expression changes, using microarrays or ‘DNA chips', in order to understand and predict breast cancer onset, progression, and clinical outcome.

Read more Medical News

› Verified 4 days ago

Vascular Access

The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.

Patients included in arterial venous fistula and catheter summaries 89
Patient months included in arterial venous fistula and catheter summaries 681
Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment54
Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer14

News Archive

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven's Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

BrainsWay receives FDA clearance for Deep TMS system to treat adults with obsessive-compulsive disorder

BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

New study shows how anterior cingulate cortex can be stimulated to control pain

A new study by a University of Texas at Arlington physics team in collaboration with bioengineering and psychology researchers shows for the first time how a small area of the brain can be optically stimulated to control pain.

Researchers profile over 6000 genes in the two primary types of normal breast cells

For several years, scientists have attempted to identify gene expression changes, using microarrays or ‘DNA chips', in order to understand and predict breast cancer onset, progression, and clinical outcome.

Read more Medical News

› Verified 4 days ago

Hospitalization Rate

The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.

Standard Hospitalization Summary Ratio(SHR) YearJanuary, 2016 - December, 2016
Patients in facility's Hospitalization Summary103
Hospitalization Rate in facility224.9 (As Expected)
Hospitalization Rate: Upper Confidence Limit351.3
Hospitalization Rate: Lower Confidence Limit154

News Archive

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven's Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

BrainsWay receives FDA clearance for Deep TMS system to treat adults with obsessive-compulsive disorder

BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

New study shows how anterior cingulate cortex can be stimulated to control pain

A new study by a University of Texas at Arlington physics team in collaboration with bioengineering and psychology researchers shows for the first time how a small area of the brain can be optically stimulated to control pain.

Researchers profile over 6000 genes in the two primary types of normal breast cells

For several years, scientists have attempted to identify gene expression changes, using microarrays or ‘DNA chips', in order to understand and predict breast cancer onset, progression, and clinical outcome.

Read more Medical News

› Verified 4 days ago

Readmission Rate

The rate of readmission show you whether patients who were being treated regularly at Texas Renal Ventures were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.

Standard Readmission Summary Ratio(SRR) YearJanuary, 2016 - December, 2016
Readmission Rate in facility26.1 (As Expected)
Readmission Rate: Upper Confidence Limit36.3
Readmission Rate: Lower Confidence Limit17.1

News Archive

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven's Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

BrainsWay receives FDA clearance for Deep TMS system to treat adults with obsessive-compulsive disorder

BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

New study shows how anterior cingulate cortex can be stimulated to control pain

A new study by a University of Texas at Arlington physics team in collaboration with bioengineering and psychology researchers shows for the first time how a small area of the brain can be optically stimulated to control pain.

Researchers profile over 6000 genes in the two primary types of normal breast cells

For several years, scientists have attempted to identify gene expression changes, using microarrays or ‘DNA chips', in order to understand and predict breast cancer onset, progression, and clinical outcome.

Read more Medical News

› Verified 4 days ago

Infection Rate

Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Texas Renal Ventures get infections in their blood each year compared to the number of infections expected for the center based on the national average.

Standard Infection Summary Ratio(SIR) YearJanuary, 2016 - December, 2016
Infection Rate in facility.28 (Better than Expected)
SIR: Upper Confidence Limit.94
SIR: Lower Confidence Limit.05

News Archive

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven's Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

BrainsWay receives FDA clearance for Deep TMS system to treat adults with obsessive-compulsive disorder

BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

New study shows how anterior cingulate cortex can be stimulated to control pain

A new study by a University of Texas at Arlington physics team in collaboration with bioengineering and psychology researchers shows for the first time how a small area of the brain can be optically stimulated to control pain.

Researchers profile over 6000 genes in the two primary types of normal breast cells

For several years, scientists have attempted to identify gene expression changes, using microarrays or ‘DNA chips', in order to understand and predict breast cancer onset, progression, and clinical outcome.

Read more Medical News

› Verified 4 days ago

Transfusion Summary

Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Texas Renal Ventures's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.

Standard Transfusion Summary Ratio (STrR) Year January, 2016 - December, 2016
Patients in facility's Transfusion Summary 84
Transfusion Rate in facility33.2 (As Expected)
Transfusion Rate: Upper Confidence Limit76.3
Transfusion Rate: Lower Confidence Limit16

News Archive

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven's Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

BrainsWay receives FDA clearance for Deep TMS system to treat adults with obsessive-compulsive disorder

BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

New study shows how anterior cingulate cortex can be stimulated to control pain

A new study by a University of Texas at Arlington physics team in collaboration with bioengineering and psychology researchers shows for the first time how a small area of the brain can be optically stimulated to control pain.

Researchers profile over 6000 genes in the two primary types of normal breast cells

For several years, scientists have attempted to identify gene expression changes, using microarrays or ‘DNA chips', in order to understand and predict breast cancer onset, progression, and clinical outcome.

Read more Medical News

› Verified 4 days ago

Survival Summary

The rate of mortality show you whether patients who were being treated regularly at Texas Renal Ventures lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.

Standard Survival Summary Ratio(SIR) YearJanuary, 2013 - December, 2016
Patients in facility's Survival Summary497
Mortality Rate in facility15.6 (As Expected)
Mortality Rate: Upper Confidence Limit20.6
Mortality Rate: Lower Confidence Limit11.6

News Archive

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven's Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

BrainsWay receives FDA clearance for Deep TMS system to treat adults with obsessive-compulsive disorder

BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

New study shows how anterior cingulate cortex can be stimulated to control pain

A new study by a University of Texas at Arlington physics team in collaboration with bioengineering and psychology researchers shows for the first time how a small area of the brain can be optically stimulated to control pain.

Researchers profile over 6000 genes in the two primary types of normal breast cells

For several years, scientists have attempted to identify gene expression changes, using microarrays or ‘DNA chips', in order to understand and predict breast cancer onset, progression, and clinical outcome.

Read more Medical News

› Verified 4 days ago


Dialysis Facility in Fort Worth, TX

RRC East Fort Worth
Location: 1032 Sandy Lane, Fort Worth, Texas, 76120
Phone: (817) 429-1944
Us Renal Care Tarrant Dialysis Fort Worth
Location: 501 College Avenue, Fort Worth, Texas, 76104
Phone: (817) 877-5907
Fresenius Medical Care Southwest Fort Worth
Location: 4804 Bryant Irvin Court, Fort Worth, Texas, 76107
Phone: (817) 738-8703
Us Renal Care Tarrant Dialysis Tarrant County
Location: 501 College Avenue, Fort Worth, Texas, 76104
Phone: (817) 877-1515
Trinity Dialysis Center
Location: 1210 Alston, Fort Worth, Texas, 76104
Phone: (817) 338-1302

News Archive

Quethera receives seed investment funding to develop gene therapy for glaucoma

Quethera, a gene therapy company developing a treatment for glaucoma that could prevent blindness, has received seed investment funding led by Midven's Rainbow Seed Fund alongside co-investor Cambridge Enterprise, the commercialisation arm of the University of Cambridge, to continue pre-clinical development of their therapy.

BrainsWay receives FDA clearance for Deep TMS system to treat adults with obsessive-compulsive disorder

BrainsWay Ltd., the parent company of BrainsWay USA, Inc., and a global leader in the advanced non-invasive treatment of brain disorders, today announces that it has received De Novo clearance from the U.S. Food and Drug Administration (FDA) for its deep transcranial magnetic stimulation (Deep TMS) system for the treatment of obsessive-compulsive disorder (OCD) in adults.

New study shows how anterior cingulate cortex can be stimulated to control pain

A new study by a University of Texas at Arlington physics team in collaboration with bioengineering and psychology researchers shows for the first time how a small area of the brain can be optically stimulated to control pain.

Researchers profile over 6000 genes in the two primary types of normal breast cells

For several years, scientists have attempted to identify gene expression changes, using microarrays or ‘DNA chips', in order to understand and predict breast cancer onset, progression, and clinical outcome.

Read more Medical News

› Verified 4 days ago


Find & Compare Providers Near You: Find and compare doctors, nursing homes, hospitals, and other health care providers in your area that accept Medicare. Get information like: Find a doctor or clinician that accepts Medicare near you.

Doctors and clinicians: Doctors and clinicians include doctors, clinicians and groups who are qualified to practice in many specialties. Each specialty focuses on certain parts of the body, periods of life, conditions, or primary care. The doctors, clinicians, and groups listed here typically work in an office or clinic setting. Also those who currently accept Medicare are included.

Hospitals: Find information about Medicare-certified hospitals and long-term care hospitals in your area, including Veterans Administration medical centers and military hospitals, across the country. Long-term care hospitals serve critically ill and medically complex patients who require extended hospital care.

Data provided: Information on www.medicareusa.org is built using open data sources published by Centers for Medicare & Medicaid Services (CMS) under Freedom of Information Act (FOIA).

© 2024 MedicareUsa. All rights reserved. Maintained by the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services.